When the F.D.A. approved the drug Aduhelm, the first Alzheimer’s treatment to receive the agency’s endorsement in almost two decades, it gave hope to many.
But the decision was contentious; some experts say there’s not enough evidence that the treatment can address cognitive symptoms.
What is the story behind this new drug?
Guest: Pam Belluck, a health and ... Show More
Yesterday
Chosen by War: The Rise of Iran’s New Supreme Leader
At the heart of the Iranian regime’s defiant stance toward the United States and Israel in the war is Mojtaba Khamenei, the new supreme leader and a son of Ayatollah Ali Khamenei, the regime’s longtime ruler. Farnaz Fassihi, who covers Iran for The New York Times, discusses the e ... Show More
33m 54s
Mar 16
A War Within the War: Israel’s Bombardment of Lebanon
With the world’s attention on the U.S.-Israeli war with Iran, a second front in the conflict has opened in Lebanon. Israel has pummeled an area in the southern outskirts of Beirut where Hezbollah holds sway, as well as southern Lebanon, with airstrikes, displacing almost one mill ... Show More
25m 58s
Mar 15
The Sunday Daily: To Save His Life, Our Food Critic Reset His Appetite
For 12 years, Pete Wells had his dream job: working as the chief restaurant critic for The New York Times. The job’s journalistic mission required Wells to eat out most nights and taste nearly everything on any given restaurant’s menu. He didn’t realize it at the time, but the ex ... Show More
37m 14s
Nov 2021
Why Aduhelm, a new Alzheimer's treatment, isn't reaching many patients
Aduhelm, known generically as aducanumab, is the first drug to actually affect the underlying disease process associated with Alzheimer's. Yet sales have been limited, and the drug is reaching very few patients — at least so far. It's expensive, risky and likely doing little to i ... Show More
9m 45s